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ABSTRACT 
Objective: The present study has focused on development and optimization of thermosensitive in-situ ocular drug delivery system for the 
treatment of conjunctivitis.  
Methods: Thermosensitive in-situ hydrogel formulation of moxifloxacin hydrochloride was developed by dispensing variable concentration of 
pluronic F-127, gellan-gum, and carbopol in distilled water. Viscosity, gelation temperature and mean release time (MRT) were measured by using 
‘Brookfield’ viscometer LV-III (spindle no. 40), rheological techniques and dissolution apparatus respectively. Optimization for ideal formulation 
was carried by ‘Box–Behnken’ design on the basis of prime factors of the formulation including viscosity, gelation temperature, and MRT. Moreover, 
the optimized formulation was evaluated for accelerated stability study by in vitro drug release, anti-microbial potential by ‘Kirby-Bauer disk 
diffusion’ method and ocular irritancy assay were done by in vivo analysis.  
Results: Optimised thermosensitive in-situ gel, when administered into cul-de-sac region of the eye, it was immediately transformed from sol to gel by 
multi-dimensional mechanism due to plurionic, gellan-gum, carbopol. The optimized formulation minimizes the chances of formulation failure as well as 
the concentration on individual polymer which dependence on a single mechanism of gelation. The final optimised formulation consists of plurionic 
(11.50% w/v), gellan-gum (0.32% w/v), carbopol (0.3% w/v), shows optimum therapeutic effect. Moreover, the accelerated stability study, anti-
microbial potential, and ocular irritancy confirmed the biocompatibility of optimized in-situ drug-containing gel with high potency and stability. 
Conclusion: Thus, optimized in-situ drug-containing gel with multifactorial approaches showed promising ocular formulation having minimum side 
effect and high therapeutic efficacy. 
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In-situ drug (gel) delivery systems concern with the conversion of 
the liquid state of a formulation (solution) into the gel at the site of 
the application under specific physiological conditions. Numerous 
factors regulate the formation of in-situ gel including temperature, 
pH, solvent exchange, ionic cross-linkage and ultraviolet-irradiation 
[1]. Since, these approaches do not need any external stimulation, 
co-polymerizing agent or organic solvents, thus attracts great 
attention of researcher [2, 3]. In-situ drug delivery systems can 
significantly reduce the concentration and frequency of daily dose, 
improve the biocompatibility, patient compliance, and cost-
effectiveness. Indeed, some earlier approaches have been made to 
enhance the ocular drug bioavailability by enhancing the precorneal 
residence time, as the drug may undergo several phases for 
transformation from sol to gel after administration into cul-de-sac 
eye region [4].  
Although, many ophthalmic in-situ gel preparations were reported 
in previous investigations, that mainly based on the principle of pH 
sensitivity (cellulose acetophthalate) [5, 6], temperature regulation 
(copolymers of poly (oxyethylene) and poly (oxypolylene)) [7, 8] 
and ionic formation (alginate and Gelrite) [9, 10]. But the 
approaches have been focused on the individual mechanism (pH 
dependent, temperature dependent or ionic dependent), made the 
final formulation become bulkier due to the high concentration of 
polymers. Additionally, the formulation becomes more expensive for 
an instance, if pluronic is considered as the main polymer, then we 
need about 30% concentration of this polymer for achieving 
sufficient gelling strength of formulation which is very high. In case 
of carbopol, the overall pH of the formulation becomes reduced due 
to self-acidic nature of carbopol and which may cause excessive 
tearing and washing of formulation [11]. Furthermore, in the case of 
gellan gum, more time is needed for gel formation, which leads to 
failure of the formulation to convert from sol into the gel before 
being washed away. Moreover, the formulation was not much 
success, as the individual polymer has its own limitations at high 
concentration including eye irritation (carbopol), thermosensitive 
(pluronic) and low rate of gelation at the site of application (gellan-
gum). Whereas, combining multiple polymers, we can formulate a 
robust formulation which reduces the chances of formulation failure 
and reduces the concentration of polymers required for the 
formulation of in-situ gel [4, 12]. Flouroquinolones are considered as 
the main drug for the treatment of pseudomonas aeruginosa 
infection [13, 14]. Moxifloxacin hydrochloride is a fluoroquinolone 
antibiotic which is generally used to treat the various bacterial 
infection such as conjunctivitis, pneumonia, endocarditis, sinusitis, 
and tuberculosis. Previously sol-to-gel system of moxifloxacin 
hydrochloride was prepared using carbopol, gellan-gum, and 
pluronic polymers individually. Thus, to overcome the limitation of 
the conventional formulation including rapid elimination, poor 
ocular bioavailability and eye irritation we have proposed the 
advanced formulation of moxifloxacin hydrochloride based on 
multifactorial approaches. We have targeted the combination of 
multiple mechanisms to form the new thermo sensitive formulation 
having a comparatively low concentration of each polymer. The 
various combinations of polymers of investigated formulations have 
been optimized by design expert software (Design-Expert® 10 
software) for maximum drug release, suitable viscosity at the ocular 
site and optimized gelation temperature. Furthermore, the ocular 
irritancy was observed in rabbit’s eye for 14 d.  
MATERIALS AND METHODS 
Material 
Moxifloxacin hydrochloride was obtained as a gift sample from 
INTAS Pharmaceuticals, Ahmadabad, India. pluronic F-127, carbopol 
934, gellan-gum were obtained as a gift sample from Jubilant Life 
Sciences India. All other chemicals were of analytical grade. 
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Microbial culture pseudomonas aueroginosa and staphylococcus 
aureus were obtained from microbial type culture collection (MTCC); 
MTCC catalogue no. of both are 424 and 96 respectively, and Gene 
Bank, CSIR-Institute of Microbial Technology, India. 
Methods 
Preparation of in-situ hydrogel and drug loading 
In-situ hydrogel system was prepared by dispersing pluronic F-127 
(10-20%) into distilled water with continues stirring for 1 hr. For 
the preparation of the gellan-gum solution, gellan-gum (0.1-0.5%) 
was dispersed into distilled water heated to 90 °C and then allowing 
to cool at room temperature with continuous stirring for 1hr. 
Carbopol (0.1-0.5) was dispersed into distilled water. Partially 
dissolved solutions of polymer were kept in a refrigerator overnight 
at 4 °C, until the entire polymer had dissolved. The in-situ hydrogel 
was prepared by mixing of the specified amount of pluronic F-127, 
gellan-gum and carbopol under continuous stirring for 1hr followed 
by over-night refrigeration. 
For the preparation of moxifloxacin hydrochloride containing in-situ 
gel, the solution of moxifloxacin hydrochloride was dispersed into a 
solution of pluronic, gellan-gum and carbopol with continuous stirring 
for 5 min followed by addition of benzalkonium chloride 
(preservative) solution. The pH of samples was adjusted at 7-7.5 by 
addition of 1 M sodium hydroxide solution. Finally, the samples were 
sterilized at 121 °C at 15 psi for 30 min and the formulation was 
refrigerated at 4 °C. Variables of the formulation were used in the 
development of in-situ formulation as described in table 1 and the 
compositions of in-situ hydrogel formulation have described in table 2. 
 
Table 1: Variables used in the formulation of thermosensitive in-situ hydrogel system 
S. No. Variables Levels 
I II III 
1 Pluronic F-127 10 15 20 
2 Gellan-gum 0.1 0.3 0.5 
3 Carbopol 0.1 0.3 0.5 
 
Table 2: Formulation composition of the in-situ hydrogel 
S. No. Ingredients  Quantity (g) 
1 Moxifloxacin hydrochloride 0.3 
2 Pluronic F-127 10-20 
3 Gellan-gum 0.1-0.5 
4 Carbopol 0.1-0.5 
5 Benzalkonium Chloride 0.006 
6 Distilled Water Quantity sufficient for 100 g 
 
Physical parameters 
The prepared in-situ hydrogel was evaluated for physical properties 
such as appearance, colour and texture etc. 
Rheological studies 
The rheological study was carried out by using Brookfield Viscometer 
LV-III. Briefly, 100 gm of the sample was taken in a beaker of 100 ml 
and viscosity was measured by using spindle no. 40.  
In vitro release study 
In vitro release studies of the prepared formulation were done with the 
help of modified dissolution apparatus. An overnight soaked semi-
permeable membrane was tied to one end of an open-ended cylindrical 
tube having the diameter of 3.2 cm. 2 ml of the test sample was placed 
into the dissolution apparatus using simulated tear (pH 7.4) as 
dissolution medium. Finally, the apparatus was suspended into the 
beaker containing 100 ml of dissolution medium, maintained at 37±2 °C 
and 50 rpm (by magnetic stirrer). Periodically 1 ml of sample was 
withdrawn and replaced by fresh dissolution medium. The aliquots were 
analysed at 287 nm using ultraviolet spectrophotometry. 
Mean release time (MRT) 







In the above equation, the european journal of pharmaceutical 
represents the time at the mid-point between i and i-l and ∆C 
represents the additional concentration of drug release between i 
and i-l [15]. 
Measurement of gelation temperature  
For the measurement of gelation temperature, 10 ml sample was 
taken and placed in 20 ml beaker. A magnetic stirring bar was placed 
in the beaker. The temperature of the sample was increased 
gradually at the rate of 1 ˚C/min and the temperature at which the 
movement of a magnetic bar was hindered was recorded as the 
gelation temperature [16, 17]. 
Design of experiment 
Experiment designing of the in-situ gel of moxifloxacin 
hydrochloride was primarily screened by trailed performed using 
variable factors like pluronic F-127, gellan-gum and carbopol. These 
trials-based screening were recognised as a significant parameter in 
formulation design for desirable drug delivery and formulation 
characteristics.  
We used Box-Behnken design (Design-Expert® 10 software) for the 
evaluation of formulation variables on product characteristics. 
About 13 runs (n=13) of the experiment were designed with 1 
centre point having randomised 200 gm batch sizes. The variable 
factors and the response data are as shown in table 1 and 2. 
Antimicrobial activity  
Antimicrobial activity was performed to evaluate the efficiency of 
the optimized formulation as compared to the marketed 
formulation. Antimicrobial activity Kirby-Bauer disk diffusion 
method was used where the drug-loaded disk of 10 mm diameter 
was incubated in nutrient agar media. Nutrient media were pre-
poured into the sterile petri plates and allowed to cool under 
laminar air flow. Microbial culture pseudomonas aueroginosa and 
staphylococcus aureus were inoculated with the help of sterile cotton 
swabs and drug-loaded disks were placed in the inoculated media. 
Finally, the petri plates were incubated at 37±0.5 °C for 24 hr. Zone 
of inhibition was measured with the help of vernier calliper [18]. 
Accelerated stability study 
Optimized formulation of moxifloxacin hydrochloride was tested for 
accelerated stability study. In brief, the optimised formulation was 
placed in glass vial closed by the grey butyl rubber closure and 
sealed with aluminium closure was stored in a stability study 
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chamber at 40±2 °C, 75±5% RH in both horizontal and vertical 
position for 1 mo. Periodically samples were withdrawn and 
evaluated for change in visual appearance, pH, gelling capacity, drug 
content and in vitro drug release [19]. 
Ocular irritancy 
Ocular irritancy test was done on rabbits eye (either sex), a weight of 
2-3 kg obtained from the institutional animal house (Amity University) 
by protocol approval number: CPCSEA/IAEC/AIP/ 2017/08/16. 
Experimental animals were acclimatised for 4 d before starting the 
experimental work. 0.1 ml of the optimized formulation of 
moxifloxacin hydrochloride was used twice a day for administration 
into the cul-de-sac for the duration of 14 d. The animals were 
evaluated for the watering of eyes, mucosal discharge and swelling. 
RESULTS AND DISCUSSION 
Physical evaluation 
The prepared in-situ gel was clear, translucent, non-gritty, uniform 
in nature.  
Rheological evaluation 
Rheological evaluation of the formulation is done to evaluate the 
viscosity of the formulation. The rheological study of the samples is 
done. The viscosity of the prepared formulation was measured for 
formulation 1 to 13 was 295, 250, 485, 255, 210, 225, 460, 475, 265, 
307, 235, 280 and 460 mPa. S consecutively (table 3).  
Evaluation of MRT 
MRT has been taken by the formulation to release it's 80% of drug 
content. MRT of the prepared formulation was evaluated. The MRT 
of the formulations 1 to 13 was measured at 2.9, 2.8, 3.1, 2.7, 2.6, 2.6, 
3.1, 2.9, 2.9, 3.1, 2.8, 2.9 and 2.9 hr. respectively (table 3).  
Gelation temperature 
Gelation temperature of the formulation indicates the temperature 
at which the phase conversion of formulation has been taken place 
from liquid to solid. The gelation temperature of the prepared 
formulations from 1 to 13 was found to be 34, 27, 17, 36, 29, 36, 24, 
33, 20, 18, 20, 27 and 26 respectively (table 3). 
  
Table 3: Composition of various factors used in thermosensitive in-situ ocular drug delivery gel of moxifloxacin hydrochloride and 
responses 
Run Factors Responses 
Pluronic F-127 Gellan-gum Carbopol MRT (h) Gelation temperature ( °C) Viscosity (mPa. S) 
1 10 0.3 0.5 2.9 34 295 
2 15 0.1 0.5 2.8 27 250 
3 20 0.5 0.3 3.1 17 485 
4 10 0.3 0.1 2.7 36 255 
5 15 0.1 0.1 2.6 29 210 
6 10 0.1 0.3 2.6 36 225 
7 15 0.5 0.5 3.1 24 460 
8 10 0.5 0.3 2.9 33 475 
9 20 0.3 0.1 2.9 20 265 
10 20 0.3 0.5 3.1 18 307 
11 20 0.1 0.3 2.8 20 235 
12 15 0.3 0.3 2.9 27 280 
13 15 0.5 0.1 2.9 26 460 
 
Table 4: Fit summery of response 1, 2 and 3. df represents the degree of freedom; PRESS represents predicted residual error sum of 
squares; statistically significant are underlined (p-value<0.005) 
Source Sum of squares df F value Prob>F p-value 
y1 y2 y3 y1 y2 y3 y1 y2 y3 y1 y2 y3 
Sequential sum of model square 
Linear 0.34 538.00 1.495E+005 3 3 3 132.60 2098.20 28.16 <0.0001 <0.0001 <0.0001 
2FI 0.000 0.000 401.00 3 3 3 0.000 0.000 0.052 0.0000 1.0000 0.9830 
Quadratic 7.692E-
003 
0.77 15105.31 3 3 3 - - 35.88 - - 0.0075 
Cubic 0.000 0.000 421.00 3 3 3 - - - - - - 
Residual 0.000 0.000 0.000 0 0 0 - - - - - - 
Total 107.37 9801.00 1.976E+006 13 13 13 - - - - - - 
Source R-squared Adjusted R-squared Predicted R-squared PRESS 
y1 y2 y3 y1 y2 y3 y1 y2 y3 y1 y2 y3 
Model summary statistics 
Linear 0.9779 0.9986 0.9037 0.9705 0.9981 0.8716 0.9640 0.9970 0.7991 0.016 1.60 33225.15 
2FI 0.9779 0.9986 0.9061 0.9558 0.9971 0.8123 0.8884 0.9928 0.5255 0.039 3.88 78494.25 
Quadratic 1.000 1.0000 0.9975 1.0000 1.0000 0.9898 - - - + + + 
Cubic - - - - 0.9927 - - - - + + + 
Details of ANOVA of response y1, y2 and y3 have described in table 5, also details of the value of multiple regression terms were analysed and 
presented in table 6. 
 
Optimization of formulation 
Independent variables including pluronic F-127, carbopol and 
gellan-gum were evaluated for their final effect on MRT, gelation 
temperature and viscosity. Total 13 experiments were conducted 
and the response data were generated in according to Box-Behnken 
design (table 3).  
Final data obtained from the experiments were well modelled by the 
independent variable linear function. Hence first order polynomial 
equation was used for approximating the function. 
y = β0+β1 χ 1+β 2 χ 2+β 3 χ 3+€. . (1) 
‘€’ represents the noise or error,  
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‘χ’ represent independent variable,  
‘y’ represents response and  
‘β’ represents the coefficient.  
The value of responses y1 (MRT), y2 (gelation temperature) and y3 
(viscosity) varies from 2.6 to 3.1 hr, 17 to 36 °C, and 210 to 485 mPa. 
S. The ratio of maximum to minimum response for response y1, y2, 
and y3 was 1.19, 2.11, and 2.3 respectively. Thus, power 
transformation was not applicable to the obtained values. The model 
section for response analyzing was according to the sequence model 
sum of square, lack of fit test and model summary statistics. The 
Prob>F value of p<0.0001, low standard deviation, high R-square 
value and lower predicted residual error sum of square (PRESS) 
value recommend to select the linear model for analysing the 
responses as detailed in table 4. 
Analysis of variance (ANOVA) was applicable to determine the effect of 
many variables and their interaction. The regression model was used 
to develop contour plots of independent factors. The ANOVA table 
affirms the competence of the liner model (Model Prob>F is less than 
0.05). It also determines the powerful factors that affect the response 
y1, y2 and y3 of the formulation. For MRT, the concentration of gellan-
gum played a significant role, followed by other 2 factors. 
Moreover, for gelation temperature, the concentration of polymer 
pluronic was determined as the significant model term, whereas for 
viscosity concentration of gellan-gum was found to be significant as 
compared to the recent investigation [20]. 
 
Table 5: ANOVA response for a surface model of MRT, gelation temperature and viscosity 
Source Sum of squares df Fvalue Prob>F P-value 
y1 y2 y3 y1 y2 y3 y1 y2 y3 y1 y2 y3 
Model 0.34 538.00 1.650E+005 3 3 9 132.60 2098.20 130.63 <0.0001 <0.0001  0.0010 
A 0.080 512.00 220.50 1 1 1 93.60 5990.40 1.57 <0.0001 <0.0001 0.2988 
B 0.18 18.00 1.152E+005 1 1 1 210.60 210.60 820.90 <0.0001 <0.0001 <0.0001 
C 0.080 8.00 34060.50 1 1 1 93.60 93.60 242.71 <0.0001 <0.0001 0.0006 
Residual 7.692E-003 0.77 421.00 9 9 3 - - - - - - 
Cor total 0.35 538.77 1.654E+005 12 12 12 - - - - - - 
 
Table 6: Value of regression term 
S. No. Terms Values 
y1 y2 y3 
1 R-squared 0.9779 0.9986 0.9975 
2 Adj R-squared 0.9705 0.9981 0.9898 
3 Pred R-squared 0.9540 0.9970 - 
4 Adeq precision 30.832 117.162 35.660 
The “Pred R-squared” value of response was found to be in reasonable agreement with the “Adj R-squared” value which indicates that the model has 
predicted the response value significantly.  
 
The eventual mathematical model determined by software design-
expert was demonstrated in Equation 2, 3 and 4. 
y1 (MRT) =+2.194+0.020 ∗ A+0.750 ∗ B+0.50∗ C. . (2) 
y2 (Gelation temp) =+54.442–1.600∗ A–7.500∗ B–5.000∗ C. . (3) 
y3 (Viscosity) =+234.625–5.400∗ A–371.250∗ B+215.00∗ C. . (4) 
The positive sign represents a synergistic effect, whereas a negative 
sign represents an antagonistic effect.  
In case of the y1 positive coefficient of A in the model refers to 
increase in MRT at higher concentration of pluronic F-127. Similarly, 
the positive coefficient of B and C indicated the increase in MRT with 
increasing other factors (pluronic, carbopol and gellan-gum 
concentration). For y2, negative coefficient of A, B, C referred to 
decrease in gelation temperature as an increase in the concentration 
of other factors. Whereas for the y3 negative coefficient of A and B 
referred to decrease in viscosity as the concentration of these factors 
increases, and positive coefficient represented the increase in the 
viscosity with an increase in the concentration of factor C. 
Theoretical and experimental response values were compared with 
each other using diagnostic case statistical report showed (table 7) 
reasonably close agreement. 
 
Table 7: Actual and predicted value of the responses, statistically significant terms are underlined (P-value less than 0.005) 
Std. order Actual value Predicted value Residual value 
y1 (h) y2 ( °C) y3(m. Pa. S) y1(h) y2( °C) y3(m. Pa. S) y1(h) y2( °C) y3(m. Pa. S) 
1 2.90 34.00 395.00 2.87 33.69 390.00 0.031 0.31 5.00 
2 2.80 27.00 350.00 2.82 27.19 350.25 -0.019 -0.19 -0.25 
3 3.10 17.00 535.00 3.12 17.19 530.25 -0.019 -0.19 4.75 
4 2.70 36.00 255.00 2.67 35.69 260.50 0.031 0.31 -5.50 
5 2.60 29.00 210.00 2.62 29.19 199.75 -0.019 -0.19 10.25 
6 2.60 36.00 275.00 2.62 36.19 279.75 -0.019 -0.19 -4.75 
7 3.10 24.00 560.00 3.12 24.19 570.25 -0.019 -0.19 -10.25 
8 2.90 33.00 525.00 2.92 33.19 519.75 -0.019 -0.19 5.25 
9 2.90 20.00 265.00 2.87 19.69 270.00 0.031 0.31 -5.00 
10 3.10 18.00 407.00 3.07 17.69 401.50 0.031 0.31 5.50 
11 2.80 20.00 285.00 2.82 20.19 290.25 -0.019 -0.19 -5.25 
12 2.90 27.00 330.00 2.87 26.69 330.00 0.031 0.31 0.000 
13 2.90 26.00 460.00 2.92 26.19 459.75 -0.019 -0.19 0.25 
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Perturbation graph was plotted to determine the factors which 
mostly affect the response. A high slope or curvature in perturbation 
graph indicates sensitivity against specific factor whereas, a 
relatively flat line indicates the less sensitivity towards that factor. In 
case of response y1 (MRT) factor B showed high slope that indicates 
higher sensitivity towards factor C, whereas factor A and C possesses 
relatively less slope indicating lesser sensitivity for response y1 (fig. 
1). For response y2, factor A showed a steep slope and factor B, and 
C shows slight slop indicating a limited effect on response y2 (fig. 2). 
Moreover, for response y3 factor B and C represented a significant 
relation, whereas factor A showed very less slope than factor B and 
C, indicating the lesser effect on response y3 (fig. 3). 
 
 




Fig. 2: Perturbation graph for effect of individual factor on 
response y2 gelation temperature 
 
By using contour plots the relationship between independent and 
dependent variable was elucidated. Fig. 4 to 6 represents the 
relationship of factors A, B and C on the responses y1, y2 and y3.  
Fig. 4 shows the effect of factor A and B on response y1 while 
keeping other factors such C at constant levels. The graph indicates 
the direct relation of concentration of factor A and B with response 
y1 (MRT). Increase in the concentration of factor A and B, showed 
the increase in MRT of the formulation. Fig. 5 shows the effect of A 




Fig. 3: Perturbation graph for effect of individual factor on 
response y3 viscosity 
 
 
Fig. 4: Contour plot of the effect of pluronic F-127 (A) and 
gellan-gum (B) on MRT 
 
 
Fig. 5: Contour plot of the effect of pluronic F-127 (A) and 
carbopol (C) on MRT 
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Fig. 6: Contour plot of the effect of gellan-gum (B) and carbopol 
(C) on MRT 
 
 
Fig. 7: Contour plot of the effect of pluronic F-127 (A) and 
gellan-gum (B) on gelation temperature 
 
The graph indicates the direct relation of response y1 (MRT) 
towards the concentration of the factor A and C. Similarly, fig. 6 
shows the effect of factor B and C on response y1, while keeping 
another factor A at a constant level. The above graph indicates the 
direct relationship of the factor B and C, with response y1 (MRT).  
Fig. 7 shows the effect of factor A and B on response y2. While 
keeping other factor C at the constant level. The above graph 
indicates the negative relation of factor A and B which revealed that 
the increase in the concentration of either of factors, the response y2 
(gelation temperature) will decrease, but factor B has less impact on 
this response as compared to factor A. Fig. 8 shows the effect of 
factor A and C on response y2 while keeping other factor B at a 
constant level. The graph also indicates the negative relation of 
factors A and C with response y2, as the increase in either of these 
factors responsible to decrease the response y2. Whereas, factor C 
having the less significant impact towards response y2. Fig. 9 shows 
the effect of factor B and C on response y2 while keeping factor A at 
a constant level. Moreover, the graph indicates the negative relation 
of factors B and C with response y2 as the increase in factor B and C 
concentration significantly reduced response y2 (gelation 
temperature). Both of these factors were showing equal significance 
toward response y2. 
 
Fig. 8: Contour plot of the effect of pluronic F-127 (A) and 
carbopol (C) on gelation temperature 
 
 
Fig. 9: Contour plot of the effect of gellan-gum (B) and carbopol 
(C) on gelation temperature 
 
 
Fig. 10: Contour plot of the effect of pluronic F-127 (A) and 
gellan-gum (B) on the viscosity 
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Fig. 10 shows the effect of factor A and B on response y3 while 
keeping factor C at a constant level. The positive relation of factor B 
with response y3 (viscosity) has observed whereas, factor A has not 
shown the significant effect on response y3. Fig. 11 shows the effect 
of factor A and C on response y3 by keeping factor B at a constant 
level. Factor C showed the positive effect on response y3 (viscosity), 
and comparatively the factor A has a very low effect on response y3. 
Moreover, fig. 12 shows the effect of factor B and C on response y3 
while keeping factor A at a constant level. Factor B and C indicates 
the positive relation between response y3. 
 
 
Fig. 11: Contour plot of the effect of pluronic F-127 (A) and 
carbopol (C) on the viscosity 
 
Gelation temperature is further important to increase the 
therapeutic efficacy of the product by increasing the moisture 
uptake and prevent the washing of dose [21]. The gelation 
temperature decreased with increase in concentration and 
molecular weight of gellan-gum. Increase in concentration of gellan-
gum further reduced the overall concentration of pluronic which 
was the main factor for controlling the gelation temperature 
whereas, increased in molecular weight of pluronic insignificantly 
increases the gelation temperature. 
 
 
Fig. 12: Contour plot of the effect of gellan-gum (B) and 
carbopol (C) on the viscosity 
 
Optimization of formulation using a graphical optimization 
method 
Optimization of the formulation was performed to determine the 
levels of factors A, B, C where yield response of y1 was 2.8 to 3.1 hr, 
y2 was 30 to 36 and y3 was 150 to 350 m. Pa. S. This model 
predicted y1, y2 and y3 in required range at A, B, and C values of 
11.50 (g), 0.32 (g), 0.3 (g) respectively for a batch size of 100 g. On 
the basis of these values, three different batches of the in-situ gel 
were prepared and found that the obtained values were the very 
close agreement to the predicted values, which establishes the 
reliability of the optimization process. In fig. 13 the overlay plot has 
shown the optimised formulation as suggested by design expert 
software for desired range response.  
Finally, the optimised concentration of variable factors was found to 
be, plurionic (11.50% w/v), gellan-gum (0.32% w/v), carbopol 
(0.3% w/v) and the final formulation is presented in table 8. 
 
Table 8: Final optimised formulation details 
S. No. Ingredients  Quantity (g) 
1 Moxifloxacin hydrochloride 0.3 
2 Pluronic F-127 11.50 
3 Gellan-gum 0.32 
4 Carbopol 0.3 
5 Benzalkonium Chloride 0.006 
6 Distilled Water Quantity sufficient for 100 g 
 
 
Fig. 13: Overlay plot for optimized parameter of in-situ hydrogel 
Accelerated stability study  
Accelerated stability studies of the optimized formulation were 
analysed periodically, but no significant change was observed in the 
visual appearance, pH, gelling capacity, drug content and in vitro 
drug release which confirm the stability of the optimized 
formulation for the long duration. 
Antimicrobial activity 
Antibacterial activity of optimized formulation was compared 
against the marketed formulation. Table 9 showed the zone of 
inhibition (ZOI) obtained by the prepared formulation of 
moxifloxacin hydrochloride as compared to the marketed 
formulation. The higher ZOI obtained by synthesized formulation 
indicate the potency of formulation that can relate the higher 
viscosity of formulation which results in slow and prolong the 
release of the formulation. 
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Table 9: Anti-bacterial potency of the synthesized and marketed formulation 
Formulation Zone of inhibition (Diameter in mm) 
Pseudomonas aueroginosa Staphylococcus aureus 
Selected Formulation  31.4±0.8 31.1±0.7 
Marketed Formulation 31.3±1.4 30.2±1.2 
*All values were represented as mean±SD (n=3).  
 
Ocular irritancy assay 
The equivalent dose of optimized formulation against marketed 
formulation has shown no ocular irritancy on rabbit eyes and for the 
duration of consecutive 14 d. No watering of eyes, mucosal discharge 
and swelling were observed during the defined period of time which 
showed the biocompatibility and no irritancy of optimized 
formulation in the biological system. 
CONCLUSION 
Optimization of the in-situ formulation using pluronic F-127, 
carbopol, gellan-gum was a complex process since it involves a large 
number of variables, which affect the characteristics of the final 
formulation. The response surface method was successfully applied 
for formulation optimization. The concentration of pluronic F-127, 
carbopol, and gellan-gum, plays a significant role in influencing MRT, 
gelation temperature and viscosity of the desired product. The 
graphical optimization helps in identifying the sweet spot, having all 
the desired physiochemical properties. The study also helps in 
providing crucial data for scale-up study or large-scale production. 
Gelation temperature was found to be more dependent on pluronic 
concentration and the MRT and viscosity of the product were found 
to be more dependable in the concentration of carbopol and gellan-
gum. The supportive study including accelerated stability study, 
antimicrobial assessment, and ocular irritancy assay proved the long 
durability with high potency and no irritancy of the optimized 
formulation. 
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